CHM.AX stock crashes 50% in after-hours trading on 16 Apr 2026

Chimeric Therapeutics Limited (CHM.AX) on the ASX experienced a severe sell-off in after-hours trading today, with CHM.AX stock plunging 50% to just A$0.001 per share. The clinical-stage cell therapy company, which develops cancer treatments including CAR-T and CAR-NK therapies, saw trading volume spike to 2.6 million shares compared to its average of 4.1 million. This dramatic decline marks another chapter in CHM.AX’s troubled history, with the stock down 70% over the past year and 99.5% from its five-year high. The biotech sector remains volatile, and Chimeric’s early-stage pipeline has yet to generate revenue, leaving investors questioning the company’s path forward.

Why CHM.AX stock collapsed today

CHM.AX stock’s 50% plunge reflects broader concerns about clinical-stage biotech companies with negative cash flow. Chimeric Therapeutics reported an operating cash flow of -A$0.0019 per share and free cash flow of -A$0.0019 per share, indicating the company burns cash to fund research. The company’s market cap sits at just A$6.6 million, making it highly sensitive to sentiment shifts. With earnings per share at -A$0.01 and no clear path to profitability, investors are reassessing risk exposure. The stock’s relative volume of 0.11 suggests below-average trading activity, which can amplify price swings in illiquid securities. Technical indicators show weakness, with the RSI at 46.64 and CCI at -66.67, both signaling bearish momentum.

CHM.AX stock price targets and valuation metrics

Chimeric Therapeutics trades at a price-to-sales ratio of 1.86, which appears reasonable on the surface but masks fundamental challenges. The company’s enterprise value of A$4.1 million is only slightly below its market cap, indicating minimal net cash. With negative book value per share of -A$0.0009, the company’s equity is technically underwater. The price-to-book ratio of -1.61 reflects this negative equity position. Meyka AI rates CHM.AX with a grade of B, suggesting a HOLD recommendation based on multiple factors including S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. The current valuation offers little margin of safety for investors given the company’s pre-revenue status.

Market sentiment and trading activity for CHM.AX stock

Trading Activity: CHM.AX stock traded 2.6 million shares today, representing 63% of its average daily volume. The day’s range was A$0.001 to A$0.002, showing extreme volatility within a narrow price band. The Money Flow Index (MFI) at 52.15 indicates neutral sentiment, while the Stochastic oscillator (%K at 83.33, %D at 94.44) suggests overbought conditions despite the decline. Liquidation Pressure: The stock’s year-to-date decline of -25% and six-month drop of -50% indicate sustained selling pressure. The current price of A$0.001 represents the stock’s 52-week low, suggesting capitulation among holders. With 4.4 billion shares outstanding, any positive catalyst would require significant volume to move the needle meaningfully.

Chimeric Therapeutics pipeline and clinical progress

Chimeric Therapeutics develops multiple cell therapy candidates targeting oncology. The company’s core NK platform (CHM 0201) is in phase I trials for solid tumors and hematological malignancies. CHM 1101 (CLTX CAR-T) is also in phase I for MMP2+ glioblastoma patients. Additional programs include CHM 0301 for blood cancers, CHM 1301 and CHM 2301 (CAR-NK therapies) for solid tumors, and CHM 2101 (CDH17 CAR-T) for neuroendocrine and gastrointestinal cancers. The company reported revenue per share of just A$0.0011, indicating minimal commercial traction. With R&D expenses at 1.65 times revenue, Chimeric is burning capital rapidly. Track CHM.AX on Meyka for real-time updates on clinical trial announcements and regulatory milestones.

Financial health and cash runway concerns

Chimeric Therapeutics faces significant financial headwinds. The current ratio of 0.69 indicates the company has only A$0.69 in current assets for every A$1.00 of current liabilities, raising liquidity concerns. Working capital stands at -A$2.3 million, meaning the company is technically insolvent on a working capital basis. The company carries minimal debt (debt-to-equity of 0.0), but this provides little comfort given negative equity. Operating losses continue to mount, with the operating profit margin at -4.58%. The company’s cash per share of A$0.00077 provides limited runway at current burn rates. Earnings are scheduled for announcement on 28 August 2026, which may provide clarity on cash position and runway. Investors should monitor quarterly cash burn closely.

Long-term outlook for CHM.AX stock

CHM.AX stock faces a challenging path forward. The company’s three-year revenue growth of -59.6% and five-year net income growth of -40.3% demonstrate deteriorating fundamentals. The stock has lost 97.9% over three years and 99.5% over five years, indicating a pattern of value destruction. However, the company’s ROE of 28.4% and ROIC of 9.9% suggest some capital efficiency, though these metrics are distorted by negative equity. For CHM.AX to recover, the company needs clinical trial success, partnership deals, or additional funding. The biotech sector remains speculative, and early-stage companies like Chimeric face binary outcomes. Investors should treat CHM.AX as a high-risk, speculative holding suitable only for those with significant risk tolerance and long time horizons.

Final Thoughts

CHM.AX stock’s 50% collapse in after-hours trading reflects the harsh reality of clinical-stage biotech investing. Chimeric Therapeutics Limited faces mounting losses, negative working capital, and a market cap of just A$6.6 million. While the company’s cell therapy pipeline targets significant oncology indications, the path from phase I trials to commercialization is long and uncertain. The stock’s 99.5% decline over five years demonstrates the risks inherent in pre-revenue biotech companies. Meyka AI’s B grade suggests a HOLD stance, but investors should carefully weigh the speculative nature of this investment. Key catalysts include clinical trial updates and potential partnerships, but these remain years away. For conservative investors, CHM.AX stock represents excessive risk. Only those with high risk tolerance and belief in the company’s science should consider exposure. Monitor cash runway and clinical progress closely before making investment decisions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.